Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Carlo Buena

Internal Medicine Las Vegas, NV Medical Doctor

NPI 1770857484 CMS profile 1603168

7061 Grand Montecito Pkwy, Las Vegas, NV 89149

Open in the dashboard

General payments

$2,927

109 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carlo Buena of Las Vegas, NV is reported in the CMS Open Payments database as having received $2,927 across 109 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $125 1
2023 General $120 1
2022 General $385 12
2021 General $354 11
2020 General $440 17
2019 General $1,502 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carlo Buena
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Carlo Buena were reported at $125. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Carlo Buena Internal Medicine median Middle half National median
2019 $1,502 $159 $48–$570 $163
2020 $440 $119 $33–$402 $114
2021 $354 $135 $37–$521 $132
2022 $385 $141 $42–$496 $149
2023 $120 $149 $45–$519 $160
2024 $0 $154 $47–$537 $164
2025 $125 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $383 21 payments
  2. AstraZeneca Pharmaceuticals LP $294 16 payments
  3. Boehringer Ingelheim Pharmaceuticals, Inc. $268 18 payments
  4. Lilly USA, LLC $266 11 payments
  5. Allergan Inc. $233 2 payments
  6. UCB, Inc. $226 2 payments
  7. EMD Serono, Inc. $220 2 payments
  8. Amgen Inc. $175 4 payments
  9. Pfizer Inc. $162 12 payments
  10. Biohaven Pharmaceuticals, Inc. $126 1 payment
  11. Other $576 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,926 108 payments
  2. Education $1 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $256 15 payments
  2. JARDIANCE $219 14 payments
  3. AIMOVIG $175 4 payments
  4. NURTEC ODT $155 3 payments
  5. BOTOX $127 1 payment
  6. Nayzilam $125 1 payment
  7. Leqembi $120 1 payment
  8. VYEPTI $115 1 payment
  9. XARELTO $108 8 payments
  10. FARXIGA $107 8 payments
  11. Other $1,153 67 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 135 drugs

Part D claims

11,773

Median for Internal Medicine: 777

Drug cost

$713,574

Median for Internal Medicine: $73,373

Branded share of claims

14.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 117 $147,762
Eliquis Apixaban Brand 142 $139,987
Ozempic Semaglutide Brand 49 $88,359
Xarelto Rivaroxaban Brand 56 $53,642
Farxiga Dapagliflozin Propanediol Brand 23 $31,540
Trulicity Dulaglutide Brand 19 $22,511
Januvia Sitagliptin Phosphate Brand 11 $16,788
Myrbetriq Mirabegron Brand 13 $16,513
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 18 $14,652
Mounjaro Tirzepatide Brand 13 $13,764

The 10 drugs with the highest cost, of 135 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$16,844

Medicare's payments for the services billed

Medicare patients

115

Average age 72

Services billed

269

68 women, 47 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 30%
Diabetes 27%
Chronic kidney disease 27%
Ischemic heart disease 20%
COPD 17%
Atrial fibrillation 11%
Depression 10%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

109 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record